本福胺对雄性大鼠胃的保护作用:一项实验研究
Mohammad Shokati Sayyad1, Mohammad Hossein Khanjani1, Milad Amirbeik1
1Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Journal of molecular histology
|August 8, 2024
概括
本福胺通过减少炎症和氧化应激,有效地保护大鼠免受印梅他辛诱导的胃. 这表明本福胺.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 胃是一种普遍的胃肠道疾病,与严重的疾病和死亡率有关.
- 胃可以提高患胃癌的风险.
研究的目的:
- 评估本福胺对雄性大鼠实验诱导的胃的胃保护作用.
- 在胃模型中研究本福胺对炎症标志物和氧化应激的影响.
主要方法:
- 三十只Wistar雄性大鼠被随机分配到对照组,受印梅他辛诱导的,奥梅普拉或本福胺 (50,100,200毫克/公斤) 治疗组.
- 胃是使用印米他辛诱导的;治疗时间为三天,然后采集样本进行分析.
- 评估胃组织损伤,促炎性细胞因子 (IL-6,TNF-α),氧化应激标志物 (MDA,ROS) 和抗氧化剂水平 (GSH).
主要成果:
- 100和200毫克/公斤的本福胺显著改善了因印梅他辛诱导的胃组织损伤.
- 被治疗的老鼠显示IL-6,TNF-α,MDA和ROS水平降低,GSH水平增加.
- 这些发现表明本福胺具有显著的抗氧化和抗炎性质.
结论:
- 本福胺在老鼠中表现出显著的胃保护作用,防止因印梅他辛诱导的胃.
- 保护机制涉及强大的抗氧化和抗炎活性.
- 需要进一步的研究来探索分子途径和临床适用性.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
423
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
423
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
362
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
362
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
380
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
380
Peptic Ulcer Disease IV: Management
79
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
79


